Fantastic news! PsyPal has reached a major milestone with the inclusion of its first patient in the multi-site clinical trial investigating psilocybin therapy for psychological and existential distress in people with progressive, life-limiting illnesses. The EPA is proud to be…
The EPA is pleased to announce its continued membership of the European Medicines Agency (EMA) Healthcare Professionals Working Party (HCPWP) for the 2025–2028 mandate. Established in 2013, the HCPWP brings together a wide range of healthcare professional organisations to provide…
Mental Health Summit: Prevention and Recovery in Modern Society European Parliament, Brussels | 19 – 20 MAY 2025 On the occasion of Mental Health Week, starting on 19 May 2025, MEP András Kulja, Vice Chair of ENVI, and SANT Vice Coordinator, together with MEP Zoltán Tarr,…
The 11th EPA Forum took place in Madrid on Saturday, 5 April 2025. The event gathered the EPA community, civil society partners, national ministries, and the EU institutions to share perspectives on mental health at work ahead of the 33rd European…
The EPA is pleased to share the Perspective on a Mentally Healthier 2035, a joint initiative of MIND, the Dutch Association of Mental Health and Addiction Care (de Nederlandse GGZ), the Netherlands Institute of Psychologists (NIP) and the Netherlands…
The EPA joined an event on psychedelic-assisted therapies at the European Parliament on 6 February 2025. This was an occasion to celebrate the launch of the PsychedeliCare European Citizen’s Initiative and the re-formation of the PAREA MEP Action Group on Psychedelics In…
The European Parliament confirmed the establishment of the first-ever Intergroup for Mental Health on 18 December 2024. The EPA welcomes this decision to give MEPs a formal platform across nationalities, committees, and political groups for collaboration on mental health as…
The EPA participated at the fourth annual edition of the Brain Innovation Days, organised by the European Brain Council, in Brussels. The event opened with a meeting at the European Parliament on 12 November, before the main conference on 13…
EPA Board Member, Pavel Mohr, attended the European Medicines Agency and Heads of Medicines Agency Multi-stakeholder Workshop on Artificial Intelligence in Amsterdam on 5 November 2024. The EMA used this occasion to update its stakeholders on developments related to AI,…
The EPA invites clinicians based in Czechia, Ireland, the Netherlands, Switzerland, and Türkiye to contribute to the Survey for Evaluating Risk of Relapse, as part of the TRUSTING project, by 17 November 2024. The survey aims to understand how clinicians in…